nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
There are three types of non-medical therapies, namely shielding by external protectors, light therapy and acupuncture. Bacterial invasion can be successfully blocked by external protectors of the nipple such as nipple shield, polyethylene film and silver cap, especially when the nipple is impaired by trauma. These protectors create a humid environment for wound recovery while defending it against bacterial infections. The silver cap consists of silver which is a natural agent with antibacterial properties. Hence it is also less likely to cause irritation. Light therapy including phototherapy and low-intensity laser therapy can treat nipple trauma as well. In the range of 630 to 1000 nm wavelength, light therapy facilitates wound recovery by promoting fibroblast proliferation, collagen synthesis, angiogenesis and growth factor production. Moreover, it can stimulate tissue regeneration, accelerate local blood flow rate through vasodilation, suppress inflammation, increase fissure healing rate, and reduce pain sensation. Recently, many review articles have suggested the effectiveness of acupuncture in treating nipple pain as it showed considerable improvement in treating breast engorgement. A 2016 Cochrane review found that a number of interventions were somewhat effective, such as hot/cold packs, Gua-Sha (scraping therapy), cabbage leaves, and proteolytic enzymes but none of the evidence supported widespread implementation.
=== Prostate cancer === Anti-androgens such as enzalutamide can be used as a treatment for prostate cancer, which, by binding to the androgen receptor, can inhibit the binding of testosterone. Androgens may promote prostate cancer, with the main androgens secreted by the testicles being testosterone and dihydroxytestosterone (DHT). Some androgens can be made by the adrenal glands, which are located above the kidneys. Abiraterone Acetate may also act as a hormone antagonist of androgens through its action as a CYP17 inhibitor. Abarelix, a GnRH antagonist may also be used for the treatment of prostate cancer.
=== Distribution in plants === Didymin is found in a variety of citrus fruits, including mandarin oranges, sweet oranges, grapefruit, and lemons, as well as in Origanum vulgare (oregano). In immature dropped fruits of Citrus sinensis, didymin has been quantified alongside other flavanone glycosides such as hesperidin and narirutin, with its content being better preserved by freeze-drying than by hot-air oven drying. It was first identified in grapefruit as a tasteless rutinoside-type flavanone glycoside, in contrast to the bitter neohesperidoside-type glycosides such as naringin. It is also present in chenpi (dried citrus peel), a traditional ingredient in Chinese medicine.
According to Wayman, Nagarjuna's explanation is as follows: "the three defilements – nescience, craving, and indulgence – give rise to the two karmas – motivations and gestation – and that these two give rise to the seven sufferings – perception, name-and-form, six sense bases, contact, feelings, re-birth, and old age and death." Vasubandhu's presentation is fully consistent with Nagarjuna's: "nescience, craving, and indulgence are defilement; motivations and gestations are karma; the remaining seven are the basis (asraya) as well as the fruit (phala). As outlined by Wayman, Asanga's Abhidharma-samuccaya divides the nidanas into the following groups:
Sources: en.wikipedia.org
== Early life and education == Gabe Logan Newell was born on November 3, 1962, at Aspen Valley Hospital in Aspen, Colorado, as the son of Donald Newell. He attended Davis Senior High School in Davis, California. He began computer programming in high school, at a time when programming was not an established career path, and imagined he would become a doctor. He worked as a paperboy, and later a telegram messenger for Western Union. In 1980, Newell enrolled at Harvard University to study programming.
3D bioprinting can be used to reconstruct tissue from various regions of the body. The precursor to the adoption of 3D printing in healthcare was a series of trials conducted by researchers at Boston Children's Hospital. The team built replacement urinary bladders by hand for seven patients by constructing scaffolds, then layering the scaffolds with cells from the patients and allowing them to grow. The trials were a success as the patients remained in good health 7 years after implantation, which led a research fellow named Anthony Atala, MD, to search for ways to automate the process. Patients with end-stage bladder disease can now be treated by using bio-engineered bladder tissues to rebuild the damaged organ. This technology can also potentially be applied to bone, skin, cartilage and muscle tissue. Though one long-term goal of 3D bioprinting technology is to reconstruct an entire organ as well as minimize the problem of the lack of organs for transplantation. There has been little success in bioprinting of fully functional organs e.g. liver, skin, meniscus or pancreas. Unlike implantable stents, organs have complex shapes and are significantly harder to bioprint. A bioprinted heart, for example, must not only meet structural requirements, but also vascularization, mechanical load, and electrical signal propagation requirements. In 2022, the first success of a clinical trial for a 3D bioprinted transplant that is made from the patient's own cells, an external ear to treat microtia, was reported.
== Coupled analysis == Following 2D SDS PAGE the proteins can be transferred to a polyvinylidene difluoride (PVDF) blotting membrane for further analysis. Edman degradations can be performed directly from a PVDF membrane. N-terminal residue sequencing resulting in five to ten amino acid may be sufficient to identify a Protein of Interest (POI).
In autumn 1981 he visited Liverpool again, this time with a thirty-strong task force of representatives of local employers and civil servants (unusually for the time, drawn from different departments – DOE, DTI and Employment, but not the Home Office this time – Heseltine had been pushing for greater cooperation between departments since the setting up of the European Space Agency in 1973). For the next fifteen months he visited Liverpool for a day almost every week, refusing police protection and often driving himself, persuading business and local government to work together. Colette Bowe, a DTI official who was deputy director of the task force, recorded that Heseltine was the most effective minister she had ever seen at getting the official machine to do his bidding through a mixture of charm and tough questions.
There were no requirements for bioequivalence in generic medications in China until the 2016 Opinion on Conducting Consistent Evaluation of the Quality and Efficacy of Generic Drugs (关于开展仿制药质量和疗效一致性评价的意见), which established basic rules for future bioequivalence work. Since July 2020, all newly approved generics must pass bioequivalence checks; previous drugs may apply to be checked. Since 2019, National Centralized Volume-Based Procurement uses "passes generic-consistency evalulation" as one of the bidding criteria. The Chinese definition of "bioequivalence" entails having the test drug's geometric mean Cmax, AUC(0–t), and AUC(0–∞) fall into 80%–125% of the reference drug in both fasting and fed states. The reference drug should be preferably the original brand-name drug, then (if not available) an internationally recognized generic approved by a developed country, then (if still not available) an internationally recognized generic approved domestically – this is to avoid deviation from the original drug by serial use of generics as reference. If pharmacokinetic values such as Cmax do not apply to the type of drug (e.g. if the drug is not absorbed orally), comparisons can be made using other means such as dose-response curves. According to Wei et al. (2022), the Consistency Evaluation Policy increased R&D spending for Chinese pharmaceutical companies, especially among private and high-yielding ones. Liu et al. (2023) argues that the Policy increased the innovation quality of the Chinese pharmaceutical industry.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.